Negative results

**FUS is not dysregulated by the spinal bulbar muscular atrophy androgen receptor polyglutamine repeat expansion**

Pietro Fratta a,b,*, Bilal Malik b,c, Anna Gray b,c, Albert R. La Spada d,e, Michael G. Hanna b, Elizabeth M.C. Fisher a,b, Linda Greensmith b,c

a Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK  
b MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London, UK  
c Sobell Department, UCL Institute of Neurology, Queen Square, London, UK  
d Division of Genetics, Department of Pediatrics, Department of Cellular and Molecular Medicine, and the Institute for Genomic Medicine, University of California-San Diego, La Jolla, CA, USA  
e Rady Children’s Hospital, San Diego, CA, USA

**A R T I C L E  I N F O**

Article history:
Received 14 May 2012  
Received in revised form 29 August 2012  
Accepted 7 September 2012  
Available online 9 October 2012

Keywords:  
Amyotrophic lateral sclerosis  
Fused in sarcoma  
TLS  
Kennedy’s Disease  
Motor neuron disease  
Spinal bulbar muscular atrophy

**A B S T R A C T**

Spinal bulbar muscular atrophy (SBMA) and amyotrophic lateral sclerosis are two distinct forms of motor neuron disease with different genetic causes, pathology, and clinical course. However, both disorders are characterized by the progressive loss of lower motor neurons and by a similar protective response to growth factors in animal models, therefore raising the possibility of an overlap in the final pathogenic cascade. Mutations in the FUS gene and fused in sarcoma (FUS) protein pathology have now been identified in some amyotrophic lateral sclerosis cases, while a CAG expansion in the androgen receptor gene is known to cause SBMA. Recently, multiple lines of evidence have identified FUS as a major target of the androgen receptor, suggesting that FUS could be dysregulated in SBMA motor neurons. We have investigated this possibility by using a well-established mouse model of SBMA and our analysis of primary motor neuron cultures, spinal cords, and microdissected motor neurons show no evidence for FUS dysregulation.

© 2013 Elsevier Inc. Open access under CC BY license.

1. Introduction

Mutations in Fused in Sarcoma (FUS) have been found to cause up to 4% of familial amyotrophic lateral sclerosis (Ferraiuolo et al., 2011). Spinal bulbar muscular atrophy (SBMA) is a slowly progressive adult-onset motor neuron (MN) disease characterized by the loss of lower MNs (LMNs) in the spinal cord and brainstem. It is caused by a CAG repeat expansion in the first exon of the androgen receptor (AR) gene which results in an extended polyglutamine tract (AR SBMA poly-Q) (Rhodes et al., 2009). The AR is a ligand-dependant transcription factor and the AR SBMA poly-Q expansion has been shown to cause disease through a variety of mechanisms, including an amplification of native AR interactions and function (Nedelsky et al., 2010).

Amyotrophic lateral sclerosis and SBMA fall under the general class of MN diseases, but have different genetic causes, pathology, and clinical course. Nonetheless, both diseases are associated by the progressive adult onset loss of LMNs, similarities in specific pathology findings, and a positive response of animal models to general protective treatments (Forsberg et al., 2012; Papanikolaou and Ellerby, 2009; Sopher et al., 2004). These findings suggest the possibility that the diseases share features in the pathogenetic cascade that leads to neuronal death (Papanikolaou and Ellerby, 2009).

Two recent independent studies, focusing on prostate cancer cells, have shown that fused in sarcoma (FUS) levels are regulated by the AR in an androgen-dependent fashion (Brooke et al., 2011; Haile et al., 2011). These results raise the possibility that FUS might be misregulated in SBMA, and this might contribute to the MN degeneration in the disease, offering an intriguing link between these 2 distinct forms of MN degeneration. Here we investigate this possible link by determining if FUS expression is dysregulated in a well characterized SBMA mouse model (AR100) carrying a 100 poly-Q expanded mutation in the AR (Sopher et al., 2004).

2. Methods

Details of mice, embryonic MN culture, laser capture microdissection, real-time quantitative polymerase chain reaction, Western
To assess the effect of the AR SBMA poly-Q repeat expansion and dihydrotestosterone (DHT) on FUS regulation in MNs, we initially determined FUS messenger RNA (mRNA) levels in purified embryonic MN (eMN) cultures obtained from AR100 and wild type (WT) littermate embryos. Taqman analysis showed that DHT treatment increases FUS levels \[ F(1,8) = 10.108; p = 0.013 \], but there was no significant difference between AR100 and WT eMNs in both DHT-treated and untreated conditions. (Fig. 1A and B).

To assess if the presence of the AR SBMA poly-Q repeat expansion caused a change in FUS levels in the context of the mature adult central nervous system, we tested FUS protein levels in spinal cord lysates of presymptomatic 3-month-old mice. The results showed no significant difference in FUS protein levels between AR100 mice and littermate controls (Fig. 1C).

FUS protein levels in the spinal cord come from an extremely diverse population of cells and this might mask possible differences present in specific cell types. We therefore analyzed FUS mRNA expression in laser capture microdissection motor neurons (MNs) of AR100 and WT mice, normalized to Actb (E) and Gapdh (F) (ns, by 2-tailed unpaired \( t \) test; \( p = 0.30, p = 0.63 \), respectively). Fused in sarcoma protein (Fus) localization is normal in 18-month-old AR100 mice MNs. Confocal images from lumbar spinal cord sections of WT (G–J) and AR100 (K–N) mice. Choline acetyltransferase (ChAT) (green), Fus (red), DAPI (blue). Fus appears to localize mainly in the nucleus of MNs and other cell types in both genotypes.

Fig. 1. FUS is normally expressed in the presence of AR100 repeat expansion. FUS messenger RNA (mRNA) levels in embryonic motor neurons, normalized to Actb (A) and Hprt1 (B). No significant (ns) change is present between AR100 and wild type (WT). A significant increase in FUS levels is present after dihydrotestosterone (DHT) treatment using 2-way analysis of variance \[ F(1,8) = 10.108; p = 0.013 \]. (C) Protein levels in 3-month-old AR100 (\( n = 6 \)) and littermate control (WT) (\( n = 5 \)) spinal cords normalized to \( \beta \)-actin (ns, by 2-tailed unpaired \( t \) test; \( p = 0.62 \)). (D) Protein levels in 12-month-old AR100 (\( n = 3 \)) and WT (\( n = 3 \)) spinal cords normalized to \( \beta \)-actin (ns, by 2-tailed unpaired \( t \) test; \( p = 0.49 \)). FUS mRNA expression in laser capture microdissection motor neurons (MNs) of AR100 and WT mice, normalized to Actb (E) and Gapdh (F) (ns, by 2-tailed unpaired \( t \) test; \( p = 0.30, p = 0.63 \), respectively). Fused in sarcoma protein (Fus) localization is normal in 18-month-old AR100 mice MNs. Confocal images from lumbar spinal cord sections of WT (G–J) and AR100 (K–N) mice. Choline acetyltransferase (ChAT) (green), Fus (red), DAPI (blue). Fus appears to localize mainly in the nucleus of MNs and other cell types in both genotypes.
levels specifically in LMNs isolated by laser capture microdissection. However, no significant changes were observed in AR100 LMNs (Fig. 1E and F).

Finally, to test if FUS dysregulation plays a role during the active disease process, we analyzed FUS protein levels in spinal cords of aged AR100 and control mice and found no significant differences (Fig. 1D). We also investigated FUS localization in lumbar spinal cord sections from end-stage AR100 and control mice. The staining revealed that FUS was localized in the nucleus throughout cells in the spinal cord and also specifically in MNs, in both genotypes (Fig. 1G–N).

4. Discussion

FUS, which when mutated can be causative of amyotrophic lateral sclerosis and is found to mislocalize in patients’ spinal cords (Ferraiuolo et al., 2011), is known to interact with nuclear hormone receptors and the AR (Haile et al., 2011; Powers et al., 1998). FUS is regulated at both the protein and mRNA levels through the AR in response to androgen stimuli (Brooke et al., 2011; Haile et al., 2011). These findings, along with the recent evidence that the mutant expanded poly-Q AR exerts part of its pathogenicity through misappropriate of native function (Nedelsky et al., 2010), have raised the question as to whether FUS could be misregulated in SBMA.

Our results show that FUS mRNA levels are increased in response to DHT in both AR100 and control purified eMNs, but no difference between AR100 and controls was found. We then analyzed if any pathologic changes occurred in vivo and, to study the direct effect of the poly-Q expanded AR, and not secondary disease changes, we chose to conduct our initial analysis at the presymptomatic age of 3 months. Both FUS protein levels in spinal cord lysates and FUS mRNA levels in microdissected MNs showed no changes between AR100 and controls. Finally, we investigated the involvement of FUS in the active phases of disease by testing mice at advanced and end-stage time points. However, even at these symptomatic stages of disease, protein levels were unchanged and FUS localization was also normal.

In conclusion, our results show that FUS expression is not altered in the spinal cord or in MNs in AR100 mice and is therefore not influenced by the presence of the poly-Q expanded AR or by secondary changes occurring in active SBMA.

Disclosure statement

The authors declare no actual of potential conflicts of interest. Mice were housed in controlled conditions in accordance with guidance issued by the Medical Research Council in Responsibility in the Use of Animals for Medical Research (1993) and all experiments were carried out under License from the UK Home Office and with Local Ethical Review panel approval.

Acknowledgements

This work was supported by a Medical Research Council/Motor Neurone Disease Association Lady Edith Wolfsion Fellowship to P.F., by grants from the Medical Research Council to E.F., the Motor Neurone Disease Association, the Brain Research Trust, and the European Community’s Seventh Framework Programme (FP7/2007–2013) to E.F. and L.G., the Institute of Neurology Kennedy’s Disease Research Fund to B.M. and L.G. L.G. is The Graham Watts Senior Research Fellow funded by the Brain Research Trust. The authors thank Ray Young for graphics, and Mr George Chennell at WIBR for technical assistance with laser capture microdissection.

Appendix A. Supplementary data

Supplementary data associated with this article and an extended version of the Introduction, Results, Methods, Discussion and References can be found, in the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.2012.09.008.

References

Brooke, G.N., Culley, R.L., Dart, D.A., Mann, D.J., Gaughan, L., McCracken, S.R., Robson, C.N., Spencer-Dene, B., Gamble, S.C., Powell, S.M., Wait, R., Waxman, J., Walker, M.M., Bevan, C.L., 2011. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res. 71, 914–924.

Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M., Shaw, P.J., 2011. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. 7, 615–630.

Forsberg, K., Jonsson, P.A., Andersen, P.M., Bergemalm, D., Graffmo, K.S., Hultdin, M., Jacobsson, J., Rosquist, R., Marklund, S.L., Brannstrom, T., 2012. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PloS One 5, e11552.

Haile, S., Lal, A., Myung, J.K., Sadar, M.D., 2011. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PloS One 6, e24197.

Nedelsky, N.B., Pennuto, M., Smith, R.B., Palazzolo, I., Moore, J., Nie, Z., Neale, G., Taylor, J.P., 2010. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67, 826–835.

Papankoulou, T., Ellerby, L.M., 2009. IGF-1: elixir for motor neuron diseases. Neuron 63, 277–278.

Powers, C.A., Mathur, M., Raaka, B.M., Ron, D., Samuels, H.H., 1998. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol. Endocrinol. 12, 4–18.

Rhodes, L.E., Freeman, B.K., Auh, S., Kokkinis, A.D., La Pean, A., Chen, C., Lehky, T.J., Shradler, J.A., Levy, E.W., Harris-Love, M., Di Prospero, N.A., Fischbeck, K.H., 2009. Clinical features of spinal and bulbar muscular atrophy. Brain 132, 3242–3251.

Sofyer, B.L., Thomas Jr, P.S., Lafave-Berntz, M.A., Holm, I.E., Wilke, S.A., Ware, C.B., Jin, I.W., Libby, R.T., Ellerby, L.M., La Spada, A.R., 2004. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and impair VEGF164 in the motor neuron degeneration. Neuron 41, 687–699.